Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

This study is testing a combination approach — lenvatinib (a targeted drug), TACE (a procedure that delivers chemotherapy directly into liver tumors via blood vessels), and camrelizumab (an immunotherapy) — to potentially shrink advanced liver cancer enough to make surgery possible. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced hepatocellular carcinoma (primary liver cancer) - You have not previously received anticancer treatment for liver cancer (or have had at most 2 TACE procedures) - Your liver function is relatively preserved (Child-Pugh class A or B) - Your cancer is in one half of the liver with involvement of the portal vein but not spreading outside the liver - Your general health status is good (ECOG score 0–1) - Your hepatitis B viral load is under control (if applicable) **You may NOT be eligible if...** - Your cancer has spread outside the liver - You have a different type of liver cancer (e.g., cholangiocarcinoma or mixed type) - You have severe liver, kidney, or blood pressure problems that are uncontrolled - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.